Literature DB >> 20511543

Tryptophan/kynurenine metabolism in human leukocytes is independent of superoxide and is fully maintained in chronic granulomatous disease.

Suk See De Ravin1, Kol A Zarember, Debra Long-Priel, King C Chan, Stephen D Fox, John I Gallin, Douglas B Kuhns, Harry L Malech.   

Abstract

In chronic granulomatous disease (CGD), defective phagocytic nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity causes reduced superoxide anion (O(2)(·)) radical production leading to frequent infections as well as granulomas and impaired wound healing indicative of excessive inflammation. Based on recent mouse studies, the lack of O(2)(·)-dependent interferon γ (IFNγ)-induced synthesis of kynurenine (kyn), an anti-inflammatory tryptophan metabolite produced by indolamine 2,3 deoxygenase (IDO), was proposed as a cause of hyperinflammation in CGD and this pathway has been considered for clinical intervention. Here, we show that IFNγ induces normal levels of kynurenine in cultures of O(2)(·)-deficient monocytes, dendritic cells, and polymorphonuclear leukocytes from gp91(PHOX)- or p47(PHOX)-deficient human CGD donors. Kynurenine accumulation was dose- and time-dependent as was that of a downstream metabolite, anthranilic acid. Furthermore, urinary and serum levels of kynurenine and a variety of other tryptophan metabolites were elevated rather than suppressed in CGD donors. Although we did not specifically evaluate kyn metabolism in local tissue or inflamed sites in humans, our data demonstrates that O(2)(·) anion is dispensable for the rate-limiting step in tryptophan degradation, and CGD patients do not appear to have either hematopoietic cell or systemic deficits in the production of the anti-inflammatory kynurenine molecule.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20511543      PMCID: PMC2947395          DOI: 10.1182/blood-2009-07-233734

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  A disorder of tryptophan metabolism in chronic granulomatous disease.

Authors:  A F Heeley; M E Heeley; J Hardy; J F Soothill
Journal:  Arch Dis Child       Date:  1970-08       Impact factor: 3.791

2.  Induction of pulmonary indoleamine 2,3-dioxygenase by interferon.

Authors:  R Yoshida; J Imanishi; T Oku; T Kishida; O Hayaishi
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

3.  Human macrophages degrade tryptophan upon induction by interferon-gamma.

Authors:  E R Werner; G Bitterlich; D Fuchs; A Hausen; G Reibnegger; G Szabo; M P Dierich; H Wachter
Journal:  Life Sci       Date:  1987-07-20       Impact factor: 5.037

4.  Studies on indoleamine 2,3-dioxygenase. I. Superoxide anion as substrate.

Authors:  F Hirata; O Hayaishi
Journal:  J Biol Chem       Date:  1975-08-10       Impact factor: 5.157

Review 5.  Genetic, biochemical, and clinical features of chronic granulomatous disease.

Authors:  B H Segal; T L Leto; J I Gallin; H L Malech; S M Holland
Journal:  Medicine (Baltimore)       Date:  2000-05       Impact factor: 1.889

6.  Thioglycollate peritonitis in mice lacking C5, 5-lipoxygenase, or p47(phox): complement, leukotrienes, and reactive oxidants in acute inflammation.

Authors:  Brahm H Segal; Douglas B Kuhns; Li Ding; John I Gallin; Steven M Holland
Journal:  J Leukoc Biol       Date:  2002-03       Impact factor: 4.962

7.  Gene expression profiling provides insight into the pathophysiology of chronic granulomatous disease.

Authors:  Scott D Kobayashi; Jovanka M Voyich; Kevin R Braughton; Adeline R Whitney; William M Nauseef; Harry L Malech; Frank R DeLeo
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

8.  Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan.

Authors:  E R Pfefferkorn
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

9.  A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease.

Authors: 
Journal:  N Engl J Med       Date:  1991-02-21       Impact factor: 91.245

10.  Leukotriene production and inactivation by normal, chronic granulomatous disease and myeloperoxidase-deficient neutrophils.

Authors:  W R Henderson; S J Klebanoff
Journal:  J Biol Chem       Date:  1983-11-25       Impact factor: 5.157

View more
  23 in total

Review 1.  Recent insights into the pathobiology of innate immune deficiencies.

Authors:  Sergio D Rosenzweig; Steven M Holland
Journal:  Curr Allergy Asthma Rep       Date:  2011-10       Impact factor: 4.806

2.  Role of brain transmigrating neutrophils in depression-like behavior during systemic infection.

Authors:  A Aguilar-Valles; A Aguliar-Valles; J Kim; S Jung; B Woodside; G N Luheshi
Journal:  Mol Psychiatry       Date:  2013-10-15       Impact factor: 15.992

3.  Tryptophan catabolism is unaffected in chronic granulomatous disease.

Authors:  Ghassan J Maghzal; Susann Winter; Bettina Wurzer; Beng H Chong; Rikard Holmdahl; Roland Stocker
Journal:  Nature       Date:  2014-10-23       Impact factor: 49.962

4.  Romani & Puccetti reply.

Authors:  L Romani; P Puccetti
Journal:  Nature       Date:  2014-10-23       Impact factor: 49.962

5.  Corticosteroid therapy for liver abscess in chronic granulomatous disease.

Authors:  Jennifer W Leiding; Alexandra F Freeman; Beatriz E Marciano; Victoria L Anderson; Gulbu Uzel; Harry L Malech; SukSee DeRavin; David Wilks; Aradhana M Venkatesan; Christa S Zerbe; Theo Heller; Steven M Holland
Journal:  Clin Infect Dis       Date:  2011-12-09       Impact factor: 9.079

6.  Local Generation of Kynurenines Mediates Inhibition of Neutrophil Chemotaxis by Uropathogenic Escherichia coli.

Authors:  Jennifer A Loughman; Melanie L Yarbrough; Kristin M Tiemann; David A Hunstad
Journal:  Infect Immun       Date:  2016-03-24       Impact factor: 3.441

7.  Cell Intrinsic Factors Modulate the Effects of IFNγ on the Development of Chlamydia trachomatis.

Authors:  Shardulendra Sherchand; Joyce A Ibana; Alison J Quayle; Ashok Aiyar
Journal:  J Bacteriol Parasitol       Date:  2016-07-25

8.  NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus.

Authors:  Allison M Campbell; Michael Kashgarian; Mark J Shlomchik
Journal:  Sci Transl Med       Date:  2012-10-24       Impact factor: 17.956

Review 9.  NOX2-dependent regulation of inflammation.

Authors:  Kelly L Singel; Brahm H Segal
Journal:  Clin Sci (Lond)       Date:  2016-04-01       Impact factor: 6.124

Review 10.  Regulation of innate immunity by NADPH oxidase.

Authors:  Brahm H Segal; Melissa J Grimm; A Nazmul H Khan; Wei Han; Timothy S Blackwell
Journal:  Free Radic Biol Med       Date:  2012-05-01       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.